TrialPloS one2021

Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial.

Maria F Paton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.